Visual Universitätsmedizin Mainz

Publikationslisten

2022

Anic K, Schmidt MW, Droste A, Schwab R, Schmidt M, Krajnak S, Renz M, Hartman EK, Hardt R, Hasenburg A, Battista MJ. Influence of anesthetic technique on survival after tumor debulking surgery of elderly patients with ovarian cancer: Results of a retrospective cohort study. Oncology Letters  24: 361, 2022.

Almstedt K, Heimes A.-S, Kappenberg F, Battista MJ, Lehr HA, Krajnak S, Lebrecht A, Gehrmann M, Stewen K, Brenner W, Weikel W, Rahnenführer J, Hengstler JG, Hasenburg A, Schmidt M. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. Eur J Cancer 173: 10-19, 2022

 Baaken D, Merzenich H, Schmidt M, Bekes I, Schwentner L, Janni W, Wöckel A, Mayr M, Mose S, Merz T, Ghilescu V, Renner J, Bartkowiak D, Wiegel T, Blettner M, Schmidberger H, Wollschläger D. A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany. Breast. 2022 Jun 9;65:1-7. doi: 10.1016/j.breast.2022.05.007. 

 

Krajnak S, Battista MJ, Hasenburg A, Schmidt M. Metronomic Chemotherapy for Metastatic Breast Cancer. Oncol Res Treat. 2022;45(1-2):12-17. doi: 10.1159/000520236. Epub 2021 Nov 18.

Krajnak S, Jäkel J, Anić K, Schwab R, Schmidt M, Hasenburg A, Roth W, Brenner W, Battista MJ. Role of integrins in the metastatic spread of high-grade serous ovarian cancer. Arch Gynecol Obstet. 2022 May;305(5):1291-1298. doi: 10.1007/s00404-021-06281-7. Epub 2021 Oct 24.

Laakmann E, Witzel I, Neunhöffer T, Park-Simon TW, Weide R, Riecke K, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Zahm DM, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry. ESMO Open. 2022 May 30;7(3):100495. doi: 10.1016/j.esmoop.2022.100495. Online ahead of print.

 

Schwab R, Droste A, Stewen K, Brenner W, Schmidt M, Hasenburg A. Patients' expectations of preventive measures of medical institutions during the SARS-CoV-2 pandemic in Germany in women with an increased risk of breast and ovarian cancer: a cross-sectional, web-based survey. BMJ Open. 2022 May 11;12(5):e060038. doi: 10.1136/bmjopen-2021-060038

 

Schmidt MW, Battista MJ, Schmidt M, Garcia M, Siepmann T, Hasenburg A, Anic K. Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials. Cancers (Basel). 2022 Jan 17;14(2):441. doi: 10.3390/cancers14020441

 

Feiten S, Scholl I, Dünnebacke J, Schmidt M, Franzen A, Ernst W, Spaderna H, Weide R. Shared decision-making in routine breast cancer care in Germany-A cross-sectional study. Psychooncology. 2022 Feb 5. doi: 10.1002/pon.5898. Online ahead of print.

 

Anic K, Altehoefer C, Krajnak S, Schmidt MW, Schwab R, Linz VC, Schmidt M, Westphalen C, Hartmann EK, Hasenburg A, Battista MJ. The preoperative G8 geriatric screening tool independently predicts survival in older patients with endometrial cancer: results of a retrospective single-institution cohort study. J Cancer Res Clin Oncol. 2022 Feb 25. doi: 10.1007/s00432-022-03934-1. 

 

Schmidt M. Das metastasierte Hormonrezeptor-positive, HER2-negative Mammakarzinom. Trillium Krebsmedizin 31 (4): 237-244, 2022

 

Decker T, Schmidt M. New Opportunities in Advanced Breast Cancer. Oncol Res Treat. 2022;45(1-2):1-3. doi: 10.1159/000521414. Epub 2021 Dec 10.

2021

 Alexa M, Hasenburg A, Battista MJ. The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions. Cancers (Basel). 2021 Mar 23;13(6):1478. 
Bartlett JMS, Bayani J, Kornaga E, Xu K, Pond GR, Piper T, Mallon E, Yao CQ, Boutros PC, Hasenburg A, Dunn JA, Markopoulos C, Dirix L, Seynaeve C, van de Velde CJH, Stein RC, Rea D. Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study. NPJ Breast Cancer. 2021 Jul 8;7(1):90.
Cotarelo CL, Zschöck-Manus A, Schmidt M, Schad A, Brochhausen C, Kirkpatrick CJ, Thaler S. Improved detection of sentinel lymph node metastases allows reliable intraoperative identification of patients with extended axillary lymph node involvement in early breast cancer. Clin Exp Metastasis. 2021 Feb;38(1):61-72. 
Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer EF, Schmitt WD, Hanusch C, Fasching PA, Lübbe K, Solbach C, Huober J, Rhiem K, Marmé F, Reimer T, Schmidt M, Sinn BV, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Jul 9:S1470-2045(21)00301-6. 
Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert US, Banys-
Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel). 2021 Jun;16(3):214-227. 
Edlund K, Madjar K, Lebrecht A, Aktas B, Pilch H, Hoffmann G, Hofmann M, Kolberg HC, Boehm D, Battista M, Seehase M, Stewen K, Gebhard S, Cadenas C, Marchan R, Brenner W, Hasenburg A, Koelbl H, Solbach C, Gehrmann M, Tanner B, Weber KE, Loibl S, Sachinidis A, Rahnenführer J, Schmidt M, Hengstler JG. Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial.  Clin Cancer Res. 2021 Apr 15;27(8):2148-2158
Erlmeier F, Steffens S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Ivanyi P. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. Clin Genitourin Cancer. 2021 Feb;19(1):53-59.e1
Gomez R, Hafezi N, Amrani M, Schweiger S, Dewenter MK, Thomas P, Lieb C, Hasenburg A, Skala C. Genetic findings in miscarriages and their relation to the number of previous miscarriages.
Genetic findings in miscarriages and their relation to the number of previous miscarriages.
Gomez R, Hafezi N, Amrani M, Schweiger S, Dewenter MK, Thomas P, Lieb C, Hasenburg A, Skala C. Arch Gynecol Obstet. 2021 Jun;303(6):1425-1432
Gomez R, Schorsch M, Skala C. Verbindung zwischen BMI und Fertilitätserfolg bei Frauen in ihren späteren reproduktiven Jahren. Journal für Gynäkologische Endokrinologie/Österreich 2021, 31 (1): 11-18   
Krakauer EL, Kane K, Kwete X, Afshan G, Bazzett-Matabele L, Ruthnie Bien-Aimé DD, Borges LF, Byrne-Martelli S, Connor S, Correa R, Devi CRB, Diop M, Elmore SN, Gafer N, Goodman A, Grover S, Hasenburg A, Irwin K, Kamdar M, Kumar S, Nguyen Truong QX, Randall T, Rassouli M, Sessa C, Spence D, Trimble T, Varghese C, Fidarova E. Augmented Package of Palliative Care for Women With Cervical Cancer: Responding to Refractory Suffering. JCO Glob Oncol. 2021 Jun;7:886-895.
Krakauer EL, Kwete X, Kane K, Afshan G, Bazzett-Matabele L, Bien-Aimé DDR, Byrne-Martelli S, Connor S, Correa R, Devi CRB, Diop M, Gafer N, Goodman A, Grover S, Hasenburg A, Irwin K, Thanh Khanh Q, Kumar S, Nevzorova D, Truong QXN, Rajagopal MR, Randall T, Rassouli M, Sessa C, Spence D, Torode JS, Trimble T, Varghese C, Fidarova E. Cervical Cancer-Associated Suffering: Estimating the Palliative Care Needs of a Highly Vulnerable Population. JCO Glob Oncol. 2021 Jun;7:862-872. 
Hasenburg A, Plett H, Krämer B, Braicu E, Czogalla B, Bossart M, Singer S, Mayr D, Staebler A, du Bois A, Kommoss S, Link T, Burges A, Heitz F, Keul J, Trillsch F, Harter P, Wimberger P, Buderath P, Klar M. The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group. Arch Gynecol Obstet. 2021 Jul 21.
Krakauer EL, Kane K, Kwete X, Afshan G, Bazzett-Matabele L, Ruthnie Bien-Aimé DD, Borges LF, Byrne-Martelli S, Connor S, Correa R, Devi CRB, Diop M, Elmore SN, Gafer N, Goodman A, Grover S, Hasenburg A, Irwin K, Kamdar M, Kumar S, Truong QXN, Randall T, Rassouli M, Sessa C, Spence D, Trimble T, Varghese C, Fidarova E. Essential Package of Palliative Care for Women With Cervical Cancer: Responding to the Suffering of a Highly Vulnerable Population. JCO Glob Oncol.
2021 Jun;7:873-885. 
Krajnak S, Loewe A, Battista MJ, Hasenburg A, Heimes AS, Schmidt M, Schwab R, Brenner W. The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells. Anticancer Res. 2021 Mar;41(3):1243-1250.
Krajnak S, Decker T, Schollenberger L, Rosé C, Ruckes C, Fehm T, Thomssen C, Harbeck N, Schmidt M. Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046. J Cancer Res Clin Oncol. 2021 Mar 20. 
Reinisch M, Seiler S, Hauzenberger T, Kamischke A, Schmatloch S, Strittmatter HJ, Zahm DM, Thode C, Furlanetto J, Strik D, Möbus V, Reimer T, Sinn BV, Stickeler E, Marmé F, Janni W, Schmidt M, Rudlowski C, Untch M, Nekljudova V, Loibl S. Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Apr 1;7(4):565-57
Riecke K, Müller V, Weide R, Schmidt M, Park-Simon TW, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Laakmann E, Thill M, A Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Witzel I. Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores. Cancers (Basel). 2021 Feb 17;13(4):844. 
Roßwag S, Cotarelo CL, Pantel K, Riethdorf S, Sleeman JP, Schmidt M, Thaler S. Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2- Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2- Breast Cancer. Cancers (Basel). 2021 Apr 10;13(8):1810.
Thill M, Friedrich M, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm T Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update2021. Breast Care (Basel). 2021 Jun;16(3):228-235. 
Schwab R, Heller M, Pfeifer C, Unger RE, Walenta S, Nezi-Cahn S, Al-Nawas B, Hasenburg A, Brenner W. Full-thickness tissue engineered oral mucosa for genitourinary reconstruction: A comparison of different collagen-based biodegradable membranes. J Biomed Mater Res B Appl Biomater. 2021 Apr;109(4):572-583.
Schwab R, Anic K, Hasenburg A. Cancer and Pregnancy: A Comprehensive Review. Cancers (Basel). 2021 Jun 18;13(12):3048. 
Schmidt M, Lenhard H, Hoenig A, Zimmerman Y, Krijgh J, Jansen M, Coelingh Bennink HJT. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J Cancer Res Clin Oncol. 2021 Jun;147(6):1833-1842. 
Schwaegermann MK, Schranz M, Moehler M, Labenz C, Moringlane A, Schmidt M, Theobald M, Hess G. Any progress in informed consenting for cancer treatment? Results from a cross sectional analysis at a comprehensive cancer center. J Cancer Res Clin Oncol. 2021  Jul;147(7):2117-2126. 
Schmidt M, KÜmmel S, Ruf-Doerdelmann A, Distelrath A, Wacker J, Schmatloch S, Busch-Liles S, LÜdtke-Heckenkamp K. Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin<sup>®</sup>) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin). Anticancer Res. 2021 Jan;41(1):485-496. 
Lüftner D, Tesch H, Schmidt M, Hartkopf AD, Streicher S, Resch A, Genovese L, Rosé C, Valenti R, Harbeck N. Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study. Eur J Cancer. 2021 Jun;150:268-277.

2020

Almstedt K, Mendoza S, Otto M, Battista MJ, Steetskamp J, Heimes AS, Krajnak S, Poplawski A, Gerhold-Ay A, Hasenburg A, Denkert C, Schmidt M. EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Jul;182(1):137-146
Blatt S, Burkhardt V, Kämmerer PW, Pabst AM, Sagheb K, Heller M, Al-Nawas B, Schiegnitz E. Biofunctionalization of porcine-derived collagen matrices with platelet rich fibrin: influence on angiogenesis in vitro and in vivo. Clin Oral Investig. 2020 Oct;24(10):3425-3436
Burghardt J, Beutel ME, Hasenburg A, Schmutzer G, Brähler E. Correction to: Declining Sexual Activity and Desire in Women: Findings from Representative German Surveys 2005 and 2016. Arch Sex Behav. 2020 Apr;49(3):927
Burghardt J, Beutel ME, Hasenburg A, Schmutzer G, Brähler E. Declining Sexual Activity and Desire in Women: Findings from Representative German Surveys 2005 and 2016. Arch Sex Behav. 2020 Apr;49(3):919-925
Canzler U, Lück HJ, Neuser P, Sehouli J, Burges A, Harter P, Schmalfeldt B, Aminossadati B, Mahner S, Kommoss S, Wimberger P, Pfisterer J, de Gregorio N, Hasenburg A, Gropp-Meier M, El-Balat A, Jackisch C, du Bois A, Meier W, Wagner U. Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group.  Arch Gynecol Obstet. 2020 May;301(5):1267-1274
Dionysopoulou A, Skala C, Weiss C, Hasenburg A, Alrich S. Establishment of a new reference line for 2D transperineal unltrasound in urogynecology. Clin J Obstet Gynecol 2020; 3: 114-119 
Erlmeier F, Steffens S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Ivanyi P. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. Clin Genitourin Cancer. 2020 Jul 9:S1558-7673(20)30149-X
Hack CC, Häberle L, Brucker SY, Janni W, Volz B, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kuemmel S, Martin B, Thomssen C, Graf H, Wolf C, Lux MP, Bayer CM, Rauh C, Almstedt K, Gass P, Heindl F, Brodkorb T, Willer L, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Rack B, Beckmann MW, Fehm T, Rody A, Maass N, Hein A, Fasching PA, Nabieva N. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. Breast. 2020 Jan 8;50:11-18
Hasenburg A, Sehouli J, Lampe B, Reuss A, Schmalfeld B, Belau AK, Bossart M, Mahner S, Hillemanns P, Petry U, du Bois A, Herwig U, Hilpert F, Gropp-Meier M, Hanf V, Greimel E, Wagner U, Harter P. Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes. Int J Gynecol Cancer. 2020 Oct;30(10):1548-1553
Hasenburg A. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86). PracticeUpdate 2, 2020
Cotarelo Cristina L., Zschoeck-Manus Annemarie, Schmidt Marcus, Schad Arno, Brochhausen Christoph, Kirkpatrick Charles James, Thaler Sonja. Improved detection of sentinel lymph node metastases allows reliable intraoperative identification of patients with extended axillary lymph node involvement in early breast cancer. CLINICAL & EXPERIMENTAL METASTASIS. 2020
Heimes AS, Härtner F, Almstedt K, Krajnak S, Lebrecht A, Battista MJ, Edlund K, Brenner W, Hasenburg A, Sahin U, Gehrmann M, Hengstler JG, Schmidt M. Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes. Int J Mol Sci. 2020 Sep 29;21(19):7178
Heller M, Bauer HK, Schwab R, Blatt S, Peters K, Nezi-Cahn S, Unger RE, Hasenburg A, Brenner W. The impact of intercellular communication for the generation of complex multicellular prevascularized tissue equivalents. J Biomed Mater Res A. 2020 Mar;108(3):734-748
Kämmerer PW, Pabst AM, Dau M, Staedt H, Al-Nawas B, Heller M. Immobilization of BMP-2, BMP-7 and alendronic acid on titanium surfaces: Adhesion, proliferation and differentiation of bone marrow-derived stem cells. J Biomed Mater Res A. 2020 Feb;108(2):212-220
Kiweler N, Wünsch D, Wirth M, Mahendrarajah N, Schneider G, Stauber RH, Brenner W, Butter F, Krämer OH. Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes. J Cancer Res Clin Oncol. 2020 Feb;146(2):343-356
Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst S, Strauss H, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeld B, Mahner S. Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study. Int J Gynecol Cancer. 2020 Jul;30(7):920-926
Krajnak S, Schnatz C, Almstedt K, Brenner W, Haertner F, Heimes AS, Lebrecht A, Makris GM, Schwab R, Hasenburg A, Schmidt M, Battista MJ. Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study.  Breast Cancer Res Treat. 2020 Jul;182(2):389-399
Westeppe S, Dionysopoulou A, Kidszun A, Schmeh I, Bartsch O, Mildenberger E, Winter J. Kagami-Ogata Syndrome: An Anomaly of the Ribs as a Pathognomonic Feature for the Clinical Diagnosis of an (epi)Genetic Syndrome. Z Geburtshilfe Neonatol. 2019 Dec 18. doi: 10.1055/a-1046-1424
Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, Baumann K, Bjørge L, Lesoin A, Burges A, Rosenberg P, Gropp-Meier M, Harrela M, Harter P, Frenel JS, Minarik T, Pisano C, Hasenburg A, Merger M, du Bois A. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. INTERNATIONAL JOURNAL OF CANCER. 2020; 146(2): 439-448
Schmidt M, Almstedt K, Heimes AS. Update aus der Immunonkologie:
Was muss ich als Kliniker verstehen? FRAUENARZT 28, 61 (2020) Nr. 1
Schmidt M. Prognostic and predictive markers for adjuvant therapy. Curr Opin Obstet Gynecol. 2020 Feb;32(1):100-105
Schönfeld M, Selig M, Russo A, Lindner C, Kampmann C, Mildenberger E, Whybra C. Rapid detection by hydrops panel of Noonan syndrome with PTPN11 mutation (p.Thr73Ile) and persistent thrombocytopenia. Mol Genet Genomic Med. 2020 May;8(5):e1174
Schwab R, Heller M, Pfeifer C, Unger RE, Walenta S, Nezi-Cahn S, Al-Nawas B, Hasenburg A, Brenner W. Full-thickness tissue engineered oral mucosa for genitourinary reconstruction: A comparison of different collagen-based biodegradable membranes. J Biomed Mater Res B Appl Biomater. 2020 Sep 10.
Ditsch Nina, Untch Michael, Kolberg-Liedtke Cornelia, Jackisch Christian, Krug David, Friedrich Michael, Janni Wolfgang, Mueller Volkmar, Albert Ute-Susann, Banys-Paluchowski Malgorzata, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Diel Ingo, Fallenberg Eva Maria, Fasching Peter A., Fehm Tanja, Gerber Bernd, Gluz Oleg, Hanf Volker, Harbeck Nadia, Heil Joerg, Huober Jens, Kreipe Hans H., Kuehn Thorsten, Kuemmel Sherko, Loibl Sibylle, Lueftner Diana, Lux Michael, Maass Nicolai, Moebus Volker, Mundhenke Christoph, Park-Simon Tjoung-Won, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Solbach Chistine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Witzel Isabell, Woeckel Achim, Thill Marc. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. BREAST CARE. 2020; 15 (3): 294-309
Ditsch N, Schmidt M.Therapie des fortgeschrittenen hormonrezeptor(HR)-positiven HER2-negativen Mammakarzinoms. Senologie. 2020; 17: 23-30
Finn Richard S., Boer Katalin, Bondarenko Igor, Patel Ravindranath, Pinter Tamas, Schmidt Marcus, Shparyk ?, Thummala Anu, Voitko Nataliia, Bananis Eustratios, McRoy Lynn, Wilner Keith, Huang Xin, Kim Sindy, Slamon Dennis J., Ettl Johannes.Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1, TRIO-18). BREAST CANCER RESEARCH AND TREATMENT. 2020; 183 (2): 419-428
Gomez R., Hafezi N., Amrani M., Schweiger S., Dewenter M. K., Thomas P., Lieb C., Hasenburg A., Skala C. Genetic findings in miscarriages and their relation to the number of previous miscarriages. ARCHIVES OF GYNECOLOGY AND OBSTETRICS. 2020
Hage Andre, Hasenburg Annette, Pietsch Michael, Heimes Anne-Sophie. MRSA and MRGN in Gynecology Retrospective Analysis of the Exposure Prevalence of MRSA and MRGN taking into account the Risk Factors queried using the Screening Form. GEBURTSHILFE UND FRAUENHEILKUNDE. 2020; 80 (07): 675-678
Heimes Anne-Sophie, Schmidt Marcus. Immunotherapy for breast cancer. GYNAKOLOGE. 2020; 53 (4): 224-228
Heimes Anne-Sophie, Kraemer Hannah, Haertner Franziska, Almstedt Katrin, Krajnak Slavomir, Battista Marco J., Brenner Walburgis, Hasenburg Annette, Schmidt Marcus. Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy. BREAST CARE. 2020
Koensgen Dominique, Battista Marco J., Egger Eva Katharina, Krajnak Slavomir, Heimes Anne-Sophie, Schmidt Marcus, Keyver-Paik Mignon-Denise, Hasenburg Annette, Mustea Alexander. New therapeutic approaches in recurrent cervical cancer. ONKOLOGE. 2020; 26 (7): 623-629
Krause Josephin C., Farthmann Juliane, Almstedt Katrin, Hasenburg Annette. Sexuality after gynecological cancer-what do affected people really need? GYNAKOLOGE. 2020; 53 (4): 251-258
Laakmann Elena, Witzel Isabell, Neunhoffer Tanja, Weide Rudolf, Schmidt Marcus, Park-Simon Tjoung-Won, Mobus Volker, Mundhenke Christoph, Polasik Arkadius, Lubbe Kristina, Hesse Tobias, Riecke Kerstin, Thill Marc, Fasching Peter A., Denkert Carsten, Fehm Tanja, Nekljudova Valentina, Rey Julia, Loibl Sibylle, Mueller Volkmar. Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases
CANCERS. 2020; 12 (10)
Nezi-Cahn Sandra, Sicking Isabel, Almstedt Kathrin, Battista Marco, Heimes Anne-Sophie, Krajnak Slavomir, Steetskamp Joscha, Hasenburg Annette, Schmidt Marcus. Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients
PHLEBOLOGIE. 2020; 49 (2): 98-107
Noordhoek Iris, Blok Erik J., Kranenbarg Elma Meershoek-Klein, Putter Hein, Duijm-de Carpentier Marjolijn, Rutgers Emiel J. T., Seynaeve Caroline, Bartlett John M. S., Vannetzel Jean-Michel, Rea Daniel W., Hasenburg Annette, Paridaens Robert, Markopoulos Christos J., Hozumi Yasuo, Portielje Johanneke E. A., Kroep Judith R., van de Velde Cornelis J. H., Liefers Gerrit-Jan. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. JOURNAL OF CLINICAL ONCOLOGY. 2020; 38 (28): 3273
Schmidt M. Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?. J Gynakol Endokrinol. 2020: 1-3
Schmidt Marcus, Lenhard Hans, Hoenig Arnd, Zimmerman Yvette, Krijgh Jan, Jansen Monique, Bennink Herjan J. T. Coelingh. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2020
Steetskamp Joscha, Bachmann Elisabeth, Hasenburg Annette, Battista Marco Johannes. Safety of misoprostol for near-term and term induction in small-for-gestational-age pregnancies compared to dinoprostone and primary cesarean section: results of a retrospective cohort study
ARCHIVES OF GYNECOLOGY AND OBSTETRICS. 2020; 302 (6): 1369-1374
Vischer Lena C., Heun Xenia, Steetskamp Joscha, Hasenburg Annette, Skala Christine. Birth experience from the perspective of the fathers. ARCHIVES OF GYNECOLOGY AND OBSTETRICS. 2020; 302 (5): 1297-1303 
Walz Cleo, Schwarz Clara-Sophie, Lebrecht Antje, Germerott Tanja. Documentation that can be Used in Court after sexualized Violence - just a few Photos? GEBURTSHILFE UND FRAUENHEILKUNDE. 2020; 80 (09): 905-910

2019

Polifka I, Agaimy A, Herrmann E,  Spath V, Trojan L, Stöckle M,
Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler
M, Stief C, Hohenfellner M, Macher-Göppinger S, Höfler H,
Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto
W, Burger M, Haferkamp A, Geppert CI, Stöhr C, Hartmann A ;          High proliferation rate and TNM-stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell. Hum Pathol. 2019 Jan;83:212-223
Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kölbl H, Reinthaller A, Woelber L, Mahner S. Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. Gynecol Oncol. 2019 Feb 11. pii: S0090-8258(19)30112-X
Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, Baumann K, Bjørge L, Lesoin A, Burges A, Rosenberg P, Gropp-Meier M, Harrela M, Harter P, Frenel JS, Minarik T, Pisano C, Hasenburg A, Merger M, du Bois A. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32606. [Epub ahead of print]
Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB,
Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J. What is the evidence for lymphadenectomy in presumed early ovarian cancer? Arch Gynecol Obstet. 2019 Jan;299(1):1-5
Schmidt M. 257b Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) e.V. zu Biomarkerbasierten Tests zur Entscheidung für oder gegen eine adjuvante systemische Chemotherapie beim primären Mammakarzinom. Geburtsh Frauenheilk. 2019; 79: 1256-1258
Schmidt M. 270. Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) zu Pertuzumab (Mammakarzinom). Gburtsh Frauenheilk. 2019; 79: 344-350
Schmidt M. 278. Stellungnahme der Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) e.V. in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e.V. der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) zu Abemaciclib (Mammakarzinom; Kombination mit Fulvestrant) – Nutzenbewertung gemäß § 35a SGB V. Geburtsh Frauenheilk. 2019; 79: 775-779
Schmidt M. 279. Stellungnahme der Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) e.V. in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e.V. der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) zu Abemaciclib (Mammakarzinom; Kombination mit einem Aromatasehemmer) – Nutzenbewertung gemäß § 35a SGB V. Geburtsh Frauenheilk. 2019; 79: 780-786
Schmidt M. 280. Stellungnahme der Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) e.V. in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e.V.(DGGG) zur Arzneimittelrichtlinie Ribociclib. Geburtsh Frauenheilk. 2019; 79: 785-794
Schmidt M. Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) e.V. zu Biomarkerbasierten Tests zur Entscheidung für oder gegen eine adjuvante systemische Chemotherapie beim primären Mammakarzinom. Geburtsh Frauenheilk. 2019; 79: 1254-1255
Schneider M, Winter J, Poplawska K, Russo AA, Lollert A, Macchiella D, Mildenberger E. Pregnancy and Maternal Chemotherapy - Side Effects for the Child? GEBURTSHILFE UND FRAUENHEILKUNDE. 2019; 79 (11): 1164-1167 Editorial Material
Schnürch HG, Ackermann S, Alt-Radtke CD, Angleitner L, Barinoff J, Beckmann MW, Böing C, Dannecker C, Fehm T, Gaase R, Gass P, Gebhardt M, Gieseking F, Günthert A, Hack CC, Hantschmann P, Horn LC, Koch MC, Letsch A, Mallmann P, Mangold B, Marnitz S, Mehlhorn G, Paradies K, Reinhardt MJ, Tholen R, Torsten U, Weikel W, Wölber L, Hampl M. Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018). Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1060-1078
Skala C, Steetskamp J, Albrich S. Klinische Relevanz des Ultraschalls in der Urogynäkologie. Frauenheilkunde up2date 2019; 13(05): 459-469
Silber S, Becker VM, Seufert R, Muensterer OJ. Fertility in males after childhood, adolescent, and adult inguinal operations. J Pediatr Surg. 2019 Jan;54(1):177-183
Stergiou Natascha, Nagel Johannes, Pektor Stefanie, Heimes Anne-Sophie, Jakel Jorg, Brenner Walburgis, Schmidt Marcus, Miederer Matthias, Kunz Horst, Roesch Frank, Schmitt Edgar
Seniorautoren: Roesch Frank, Schmitt Edgar
Autoren der Einrichtung: Heimes Anne-Sophie, Brenner Walburgis, Schmidt Marcus
Weitere Autoren des Fachbereichs: Stergiou Natascha, Pektor Stefanie, Jakel Jorg, Miederer Matthias, Schmitt Edgar
Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES. 2019; 16 (9): 1188-1198
Stergiou N, Gaidzik N, Heimes AS, Dietzen S, Besenius P, Jäkel J, Brenner W, Schmidt M, Kunz H, Schmitt E.                                   Reduced breast tumor growth after immunization with a tumor-restricted MUC1 glycopeptide conjugated to tetanus toxoid. Cancer Immunol Res. 2019 Jan;7(1):113-122
Stewen K, Theis S, Teifke A, Kohlwes E, Hasenburg A. Benigne und präinvasive Läsion der Brust. Frauenheilkunde up2date 2019, 13(5): 423-439 
Thill M, Jackisch C, Janni W, Müller V, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Wenz F, Witzel I, Wöckel A, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care (Basel). 2019 Aug;14(4):247-255
Weikel W. Lymphonodektomie beim Vulvakarzinom: Wann und wie vorgehen? Frauenheilkunde up2date 2019, 13(4): 355-365
Westeppe S, Dionysopoulou A, Kidszun A, Schmeh I, Bartsch O, Mildenberger E, Winter J. Kagami-Ogata Syndrome: An Anomaly of the Ribs as a Pathognomonic Feature for the Clinical Diagnosis of an (epi)Genetic Syndrome. Z Geburtshilfe Neonatol. 2019 Dec 18. doi: 10.1055/a-1046-1424
Wiesmann N, Kluenker M, Demuth P, Brenner W, Tremel W, Brieger J.Zinc overload mediated by zinc oxide nanoparticles as innovative anti-tumor agent. J Trace Elem Med Biol. 2019 Jan;51:226-234
Willershausen I, Schmidtmann I, Azaripour A, Kledtke J, Willershausen B, Hasenburg A. Association between breast cancer chemotherapy, oral health and chronic dental infections: a pilot study. Odontology. 2019 Jan 21. doi: 10.1007/s10266-019-00411-z
Wunderle M, Pretscher J, Brucker SY, Volz B, Hartmann A, Fiessler C, Hein A, Häberle L, Jud SM, Lux MP, Janni W, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kümmel S, Martin B, Thomssen C, Graf H, Wolf C, Bayer CM, Hack CC, Almstedt K, Gass P, Heindl F, Brodkorb TF, Nabieva N, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Wallwiener D, Rack B, Fehm T, Rody A, Maass N, Beckmann MW, Fasching PA, Rauh C. Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Res Treat. 2019 Apr;174(2):453-461

2018

Bartkowiak, D., Buehrdel, S., Wiegel, T., Wollschlaeger, D., Merzenich, H., Blettner, M., Karle, H., Stockinger, M., Schmidberger, H., Schmidt, M., et al. (2018a). Lack of evidence for cardiac effects of breast cancer irradiation. Strahlenther. Onkol. 194, S82–S83.


Bartkowiak, D., Merzenich, H., Wollschlager, D., Karle, H., Stockinger, M., Schmidt, M., Blettner, M., Schmidberger, H., Wockel, A., Janni, W., et al. (2018b). Results from the PASSOS heart study. Oncol. Res. Treat. 41, 1–1.


Bartlett, J.M.S., Bayani, J., Kornaga, E., Piper, T., Mallon, E., Yao, C.Q., Boutros, P.C., Hasenburg, A., Kieback, D.G., Markopoulos, C., et al. (2018a). Comparative survival analysis of multiparametric tests in the TEAM pathology study: What to do when molecular tests disagree? Cancer Res. 78.


Bartlett, J.M.S., Thomas, J., Mallon, E., Piper, T., Bayani, J., Hasenburg, A., Kieback, D.G., Markopoulos, C., Dirix, L., Seynaeve, C., et al. (2018b). Simplified histological grading of breast carcinoma - potential for improved concordance and consistency in breast cancer grading? Cancer Res. 78.


Bayani, J., Crozier, C., Quintayo, M.A., Amemiya, Y., Zhang, X., Lariviere, M., Sadis, S., Smith, J.M., Hasenburg, A., Kieback, D., et al. (2018a). Evaluation of the oncomine comprehensive assay for the identification of actionable mutations for therapeutic stratification from the TEAM pathology cohort. Cancer Res. 78.


Bayani, J., Kornaga, E.N., Crozier, C., Jang, G.H., Kalatskaya, I., Trinh, Q.M., Yao, C.Q., Livingstone, J., Hasenburg, A., Kieback, D.G., et al. (2018b). Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers. Cancer Res. 78.


de Boniface, J., Schmidt, M., Engel, J., Smidt, M.L., Offersen, B.V., and Reimer, T. (2018). What Is the Best Management of cN0pN1(sn) Breast Cancer Patients? Breast Care 13, 331–336.
Breuksch, I., Welter, J., Bauer, H.-K., Enklaar, T., Frees, S., Thüroff, J.W., Hasenburg, A., Prawitt, D., and Brenner, W. (2018). In renal cell carcinoma the PTEN splice variant PTEN-Δ shows similar function as the tumor suppressor PTEN itself. Cell Communication and Signaling 16.


Chekerov, R., Hilpert, F., Mahner, S., El-Balat, A., Harter, P., De Gregorio, N., Fridrich, C., Markmann, S., Potenberg, J., Lorenz, R., et al. (2018). Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology 19, 1247–1258.


Coombes, R.C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., Hicks, J., Makris, A., Evans, A., Loibl, S., et al. (2018). A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial). Cancer Res. 78.


Derks, M.G.M., Bastiaannet, E., van de Water, W., de Glas, N.A., Seynaeve, C., Putter, H., Nortier, J.W.R., Rea, D., Hasenburg, A., Markopoulos, C., et al. (2018). Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. European Journal of Cancer 99, 1–8.


Eckes, L., Droge, L.A., Fullborn, T., Harter, P., Mustea, A., Muallem, M.Z., Wimberger, P., Mahner, S., Kurzeder, C., Hasenburg, A., et al. (2018). Management of patients with gynecological sarcoma - a survery among gynecologists within the framework of the German Registry of Gynecological Sarcoma (REGSA). Oncol. Res. Treat. 41, 194–195.


Feiten, S., Scholl, I., Schmidt, M., Duennebacke, J., Franzen, A., Ernst, W., and Weide, R. (2018). Shared decision making (SDM) in routine care treatment of breast cancer patients - a survey of patients following surgery. Cancer Res. 78.


Frees, S., Breuksch, I., Haber, T., Bauer, H.-K., Chavez-Munoz, C., Raven, P., Moskalev, I., D´Costa, N., Tan, Z., Daugaard, M., et al. (2018). Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma. Oncotarget 9.


Galetzka, D., Boeck, J., Dittrich, M., Zahnreich, S., Altebockwinkel, I., Sinizyn, O., Rossmann, H., Spix, C., Breuksch, I., Prawitt, D., et al. (2018). Factors leading to changes in methylation of intron 2 in RAD9A gene and their possible influence in tumor development. Strahlenther. Onkol. 194, S56–S56.


de Gregorio, N., Harter, P., Kimmig, R., Reuss, A., Pfisterer, J., Hilpert, F., Meier, W., Hanker, L., Canzler, U., Sehouli, J., et al. (2018). Overall survival results of AGO-OVAR 12, a randomized placebo-controlled multinational phase III trial with chemotherapy plus /- nintedanib in patients with advanced primary ovarian cancer. Oncol. Res. Treat. 41, 88–88.


Hartmann, K., Schlombs, K., Laible, M., Gürtler, C., Schmidt, M., Sahin, U., and Lehr, H.-A. (2018). Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue. Diagnostic Pathology 13.
Hasenburg, A. (2018). Primary Therapy of Ovarian Cancer. Gynakologe 51, 598–598.


Hasenburg, A., Harter, P., Park-Simon, T.-W., Gropp-Meier, M., Heitz, F., Soergel, P., Ataseven, B., Friedlaender, M., Hilpert, F., and Pujade-Lauraine, E. (2018a). Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III. Oncol. Res. Treat. 41, 88–89.


Hasenburg, A., Sehouli, J., Lampe, B., Reuss, A., Schmalfeldt, B., and Belau, A.K. (2018b). LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women-Prospective substudy of the randomized multicenter LION study. J. Clin. Oncol. 36.


Heimes, A.-S., Jaekel, J., Weyer-Elberich, V., Almstedt, K., Krajnak, S., Elger, T., Brenner, W., Schmidt, M., Hasenburg, A., and Battista, M. (2018). A retrospective analysis of immunohistochemically determined IRF4 expression in a consecutive cohort of 114 ovarian cancer patients. Oncol. Res. Treat. 41, 92–92.


Heitz, F., Harter, P., Kimmig, R., Reuss, A., Gregorio, N.D., Pfisterer, J., Hilpert, F., Meier, W., Hanker, L., Canzler, U., et al. (2018). The prognostic value of tumor residuals (TR) indicated by surgeon (SA), by radiology (RA), or an integrated approach (IA) by surgeons’ assessment and pre-chemotherapy CT-scan in patients with advanced ovarian cancer: An exploratory analysis of the AGO led Intergroup trial AGO-OVAR 12. Oncol. Res. Treat. 41, 12–12.


Hillemanns, P., Sehouli, J., Harter, P., Reuss, A., Meier, W., Hasenburg, A., Hilpert, F., Neuenhoeffer, T., Denschlag, D., Burges, A., et al. (2018). Phase III Randomized Controlled Study to Evaluate the Impact of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer - AGO Desktop III / ENGOT OV20. Oncol. Res. Treat. 41, 11–11.


Honecker, F., Harbeck, N., Schnabel, C., Wedding, U., Waldenmaier, D., Saupe, S., Jaeger, E., Schmidt, M., Kreienberg, R., Mueller, L., et al. (2018). Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. J. Geriatr. Oncol. 9, 163–169.


Huebner, H., Fasching, P.A., Gumbrecht, W., Jud, S., Rauh, C., Matzas, M., Paulicka, P., Friedrich, K., Lux, M.P., Volz, B., et al. (2018). Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. BMC Cancer 18.


Huss, A., Ihorst, G., Timme-Bronsert, S., Hasenburg, A., Oehler, M.K., and Klar, M. (2018). The Memorial Sloan Kettering Cancer Center Nomogram is More Accurate than the 2009 FIGO Staging System in the Prediction of Overall Survival in a German Endometrial Cancer Patient Cohort. Ann. Surg. Oncol. 25, 3966–3973.


Kebenko, M., Goebeler, M.-E., Wolf, M., Hasenburg, A., Seggewiss-Bernhardt, R., Ritter, B., Rautenberg, B., Atanackovic, D., Kratzer, A., Rottman, J.B., et al. (2018). A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. OncoImmunology e1450710.


Kiweler, N., Brill, B., Wirth, M., Breuksch, I., Laguna, T., Dietrich, C., Strand, S., Schneider, G., Groner, B., Butter, F., et al. (2018). The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. Archives of Toxicology 92, 2227–2243.


Krajnak, S., Battista, M., Brenner, W., Almstedt, K., Elger, T., Heimes, A.-S., Hasenburg, A., and Schmidt, M. (2018). Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients. Breast Care 13, 272–276.


Loibl, S., Barinoff, J., Seiler, S., Decker, T., Denkert, C., Hardy-Bessard, A.-C., Senkus-Konefka, E., Cognetti, F., Palmieri, C., Gelmon, K., et al. (2018). A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA). Cancer Res. 78.


Lorenz, E., Blettner, M., Lange, B., Schmidt, M., Schneider, A., Schwentner, L., Wollschläger, D., and Merzenich, H. (2018). Prevalence of Cardiac Disease in Breast Cancer Patients at Time of Diagnosis Compared to the General Female Population in Germany. Breast Care 13, 264–271.


Merzenich, H., Blettner, M., Niehoff, D., Schwentner, L., Schmidt, M., Schmitt, M., and Wollschläger, D. (2018a). Cardiac late events in German breast cancer patients: a validation study on the agreement between patient self-reports and information from physicians. BMC Cardiovascular Disorders 18.


Merzenich, H., Wollschläger, D., Almstedt, K., Schmidt, M., Blettner, M., Schmidberger, H., and Stockinger, M. (2018b). Kardiale Spätfolgen nach Strahlentherapie und Chemotherapie. Der Onkologe 24, 780–789.


Mobus, V., Mahlberg, R., Janni, W., Tome, O., Marme, F., Forstbauer, H., Reimer, T., von der Assen, A., Reinisch, M., Lorenz, R., et al. (2018). Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study. Cancer Res. 78.


Moebus, V., Noeding, S., Ladda, E., Klare, P., Schmidt, M., Schneeweiss, A., Janni, W., Marme, F., Reimer, T., Schmatloch, S., et al. (2018). Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting. J. Clin. Oncol. 36.


Mueller, V., Park-Simon, T.-W., Huober, J., Schmidt, M., Weide, R., Reinisch, M., Fehm, T., Salat, C., Loibl, S., Schem, C., et al. (2018). A randomized, double-blinded pivotal study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. unresectable locally advanced or metastatic breast cancer: HER2CLIMB. Oncol. Res. Treat. 41, 28–28.


Münster, E., Letzel, S., Passet-Wittig, J., Schneider, N.F., Schuhrke, B., Seufert, R., and Zier, U. (2018). Who is the gate keeper for treatment in a fertility clinic in Germany? -baseline results of a prospective cohort study (PinK study)-. BMC Pregnancy and Childbirth 18.


Pleimes, D., Moebus, V., Mayer, F., Schmidt, M., Asang, C., Flunkert, K., and Mikus, G. (2018). Induced Myerosuppression and Recommendation for Monitoring of Absolute Neutrophil Counts in Patients Treated with Epirubicin and Cyclophosphamide in Early Breast Cancer: Results from a Phase 2a Collaborative Trial of the AGO-B and CESAR Study Groups. Blood 132.


Pradella, F., Leimer, B., Fruth, A., Queisser, A., and van Ewijk, R. (2018). Health effects of in utero exposure to Ramadan: A survey study among pregnant Muslim women in Germany. Eur. J. Public Health 28, 487–487.


Reimer, T., Engel, J., Schmidt, M., Offersen, B.V., Smidt, M.L., and Gentilini, O.D. (2018). Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery? Breast Care 13, 324–330.


Reinisch, M., Seiler, S., Hauzenberger, T., Schmatloch, S., Strittmatter, H., Zahm, D.M., Thode, C., Jackisch, C., Furlanetto, J., Strik, D., et al. (2018). Male-GBG54: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen plus /- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor plus GnRHa in male breast cancer patients. Cancer Res. 78.


Roseweir, A.K., Bennett, L., Dickson, A., Cheng, K., Quintayo, M.-A., Bayani, J., McMillan, D.C., Horgan, P.G., van de Velde, C.J.H., Seynaeve, C., et al. (2018). Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. JNCI: Journal of the National Cancer Institute 110, 616–627.


Schmidt, M., and Gerlach, C. (2018). Palliativmedizinische Maßnahmen bei gynäkologischen Malignomen und Mammakarzinomen gemäß S3 - Leitlinie. Der Gynäkologe 51, 859–869.


Schmidt, M., and Sebastian, M. (2018). Palbociclib—The First of a New Class of Cell Cycle Inhibitors. In Small Molecules in Oncology, U.M. Martens, ed. (Cham: Springer International Publishing), pp. 153–175.


Schmidt, M., Decker, T., Fehm, T., Fuxius, S., Harbeck, N., Juhasz-Boess, I., Thomssen, C., Seehase, M., Schollenberger, L., Ruckes, C., et al. (2018a). A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR plus ) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro. Cancer Res. 78.


Schmidt, M., Weyer-Elberich, V., Hengstler, J.G., Heimes, A.-S., Almstedt, K., Gerhold-Ay, A., Lebrecht, A., Battista, M.J., Hasenburg, A., Sahin, U., et al. (2018b). Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Research 20.


Schwab, R., Rautenberg, B., Weis, J., and Hasenburg, A. (2018). Schwangerschaft und Krebs: psychoonkologische Beratung zur Fertilität. Der Onkologe 24, 552–555.


Singer, S., Claus, S., Briest, S., Stolzenburg, J.-U., Papsdorf, K., Gockel, I., Köhler, U., Oestreicher, G., Heß, G., Schmidt, M., et al. (2018). Positive und negative Veränderungen im Leben nach der Krebsdiagnose: Eine prospektive Mixed-Method-Studie. Der Onkologe 24, 411–419.


Surowy, H., Varga, D., Burwinkel, B., Marmé, F., Sohn, C., Luedeke, M., Rinckleb, A., Maier, C., Deissler, H., Volcic, M., et al. (2018). A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity: Role of haplotype spanning SLX4/FANCP in BC. International Journal of Cancer 142, 757–768.


Thaler, S., Schad, A., Kirkpatrick, C.J., Sleeman, J.P., Springer, E., Schmidt, M., and Cotarelo, C.L. (2018). Cellular senescence within HER2-amplified breast cancer: Potential implications for breast cancer immune surveillance and HER2-targeted therapy resistance. Cancer Res. 78.


Thill, M., and Schmidt, M. (2018). Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Therapeutic Advances in Medical Oncology 10, 175883591879332.


Thill, M., Liedtke, C., Müller, V., Janni, W., Schmidt, M., and on behalf of the AGO Breast Committee (2018a). AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018. Breast Care 13, 209–215.


Thill, M., Schmidt, M., Lux, M., Liedtke, C., Schneeweiss, A., and Jackisch, C. (2018b). Einführung und Verwendung von biosimilaren Antikörpern in der Therapie des Mammakarzinoms. Geburtshilfe und Frauenheilkunde 78, 41–44.


Witzel, I., Laakmann, E., Weide, R., Neunhöffer, T., Park-Simon, T.-J., Schmidt, M., Fasching, P.A., Hesse, T., Polasik, A., Mohrmann, S., et al. (2018). Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. European Journal of Cancer 102, 1–9.


Wöckel, A., Festl, J., Stüber, T., Brust, K., Stangl, S., Heuschmann, P., Albert, U.-S., Budach, W., Follmann, M., Janni, W., et al. (2018a). Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe und Frauenheilkunde 78, 927–948.


Wöckel, A., Festl, J., Stüber, T., Brust, K., Krockenberger, M., Heuschmann, P., Jírů-Hillmann, S., Albert, U.-S., Budach, W., Follmann, M., et al. (2018b). Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe und Frauenheilkunde 78, 1056–1088.

2017

Affolter A, Samosny G, Heimes AS, Schneider J, Weichert W, Stenzinger A, Sommer K, Jensen A, Mayer A, Brenner W, Mann WJ, Brieger J. Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. Head Neck. 2017 Apr;39(4):623-632

Albrich, S.B., Welker, K., Wolpert, B., Steetskamp, J., Porta, S., Hasenburg, A., and Skala, C. (2017). How common is ballooning? Hiatal area on 3D transperineal ultrasound in urogynecological patients and its association with lower urinary tract symptoms. Arch. Gynecol. Obstet. 295, 103–109.


Almstedt, K., Sicking, I., Battista, M.J., Huangfu, S., Heimes, A.-S., Weyer-Elberich, V., Hasenburg, A., and Schmidt, M. (2017). Prognostic Significance of Focal Adhesion Kinase in Node-Negative Breast Cancer. Breast Care 12, 329–333.


Barinoff, J., Schmidt, M., Schneeweiss, A., Schoenegg, W., Thill, M., Keitel, S., Lattrich, C.R., Hinke, A., Kutscheidt, A., and Jackisch, C. (2017). Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery. Eur. J. Cancer 83, 116–124.


Bartlett, J., Kalatskaya, I., Yousif, F., Bayani, J., Trinh, Q.M., Heisler, L., Timms, L., Lee, S., Buchner, N., Milacic, M., et al. (2017). Targeted sequencing in a phase III trial of luminal breast cancer: Identification of novel targets. J. Clin. Oncol. 35.


Battista, M.J., Schanz, V., Schmidt, M., Krajnak, S., Elger, T., Heimes, A.S., Maurer, S., Steiner, E., Eichbaum, M., Mallmann, P., et al. (2017). Changes of the Therapeutic Approaches for Endometrial Cancer Patients in Germany Since 2006. Int. J. Gynecol. Cancer 27, 1041–1041.


Baumann, F.T., Hasenburg, A., Jahn, P., Leitzmann, M., Mumm, A., Schulte-Frei, B., and Wiskemann, J. (2017). Excercise is medicine in oncology. On the way to becoming a standard pillar in the treatment of cancer patients. Onkologe 23, 1021–1030.


Bayani, J., Kornaga, E., Crozier, C., Jang, G.H., Kalatskaya, I., Trinh, Q.M., Yao, C.Q., Livingstone, J., Hasenburg, A., Kieback, D.G., et al. (2017a). Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers. J. Clin. Oncol. 35.


Bayani, J., Yao, C.Q., Quintayo, M.A., Yan, F., Haider, S., D’Costa, A., Brookes, C.L., van de Velde, C.J.H., Hasenburg, A., Kieback, D.G., et al. (2017b). Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. Npj Breast Cancer 3, UNSP 3.


Breuksch, I., Prosinger, F., Baehr, F., Engelhardt, F.-P., Bauer, H.-K., Thueroff, J.W., Heimes, A.-S., Hasenburg, A., Prawitt, D., and Brenner, W. (2017a). Integrin alpha 5 triggers the metastatic potential in renal cell carcinoma. Oncotarget 8, 107530–107542.


Breuksch, I., Schmidt, M., Hengstler, J., Edlund, K., Gebhard, S., Prawitt, D., Hasenburg, A., and Brenner, W. (2017b). The role of the splice variant PTENdelta in tumor progression. Int. J. Mol. Med. 40, S15–S15.


Dappa, E., Elger, T., Hasenburg, A., Dueber, C., Battista, M.J., and Hoetker, A.M. (2017). The value of advanced MRI techniques in the assessment of cervical cancer: a review. Insights Imaging 8, 471–481.


Eckes, L., Harter, P., Muallem, M.Z., Fuellborn, T., Mustea, A., Dengler, M., Rengsberger, M., Anthuber, C., Emons, G., Weigel, M., et al. (2017a). First Results of the German Prospective Registry for Gynecological Sarcomas (regsa): A Collaboration of Noggo, Ago Study Group, Ago Kommission Ovar, Ago Kommission Uterus, Aro. Int. J. Gynecol. Cancer 27, 1323–1323.


Eckes, L., Harter, P., Muallem, M.Z., Fuellborn, T., Mustea, A., Dengler, M., Rengsberger, M., Anthuber, C., Emons, G., Weigel, M., et al. (2017b). First Results of the German Prospective Registry for Gynecological Sarcomas (regsa): A Collaboration of Noggo, Ago Study Group, Ago Kommission Ovar, Ago Kommission Uterus, Aro. Int. J. Gynecol. Cancer 27, 247–247.


Elger, T., Battista, M., Krajnak, S., Heimes, A.S., Hasenburg, A., and Schmidt, M. (2017a). Weekly Paclitaxel in Refractory Choriocarcinoma. Int. J. Gynecol. Cancer 27, 1324–1324.


Elger, T., Battista, M., Macchiella, D., Krajnak, S., Maurer, S., Hasenburg, A., and Rommens, K. (2017b). Yolk Sac Tumor of the Clitoris in a Fifteen-Months-Old Child. Int. J. Gynecol. Cancer 27, 1325–1325.


Finn, R.S., Crown, J., Lang, I., Boer, K., Bondarenko, I., Kulyk, S.O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2017). Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2-advanced breast cancer (PALOMA-1; TRIO-18). J. Clin. Oncol. 35.


Frees, S., Haber, T., Moskalev, I., Breuksch, I., Struss, W., Thuroff, J., Gleave, M., Prawitt, D., So, A., and Brenner, W. (2017a). The Calcium-Sensing Receptor (casr) Is Responsible for the Development. J. Urol. 197, E792–E792.


Frees, S., Kamal, M., Nestler, S., Bidnur, S., Brenner, W., Jaeger, W., Thomas, C., Neisius, A., Thueroff, J., and Roos, F. (2017b). Are the Current Follow-up Guidelines After Treatment for Organ Confined Renal Cancer Sufficient? J. Urol. 197, E914–E914.


Harbeck, N., Saupe, S., Jaeger, E., Schmidt, M., Kreienberg, R., Mueller, L., Otremba, B.J., Waldenmaier, D., Dorn, J., Warm, M., et al. (2017). A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res. Treat. 161, 63–72.


Hasenburg, A., Farthmann, J., and Schwab, R. (2017a). Sexuality after gynecological cancer. Gynakologe 50, 333–338.


Hasenburg, A., Weis, J., Schwab, R., Kesic, V., Bjelic-Radisic, V., Ottevanger, N., van Dorst, E., Greimel, E., and Mijalkovic, S. (2017b). Psycho-oncology in oncofertility: Fertility and quality of life in cancer patients. Psycho-Oncol. 26, 165–166.


Heimes, A.S., Schmidt, M., Jaekel, J., Almstedt, K., Gebhard, S., Weyer-Elbereich, V., Elger, T., Krajnak, S., Brenner, W., Hasenburg, A., et al. (2017a). A Retrospective Analysis of Immunohistochemical Determined Irf4 (interferon Regulating Factor 4) Expression in a Consecutive Cohort of 114 Ovarian Cancer Patients. Int. J. Gynecol. Cancer 27, 1520–1520.


Heimes, A.-S., Madjar, K., Edlund, K., Battista, M.J., Almstedt, K., Elger, T., Krajnak, S., Rahnenfuehrer, J., Brenner, W., Hasenburg, A., et al. (2017b). Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer. Breast Cancer Res. Treat. 165, 293–300.


Heimes, A.-S., Madjar, K., Edlund, K., Battista, M.J., Almstedt, K., Gebhard, S., Foersch, S., Rahnenfuehrer, J., Brenner, W., Hasenburg, A., et al. (2017c). Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. J. Cancer Res. Clin. Oncol. 143, 1123–1131.


Heimes, A.-S., Stewen, K., and Hasenburg, A. (2017d). Psychosocial Aspects of Immediate versus Delayed Breast Reconstruction. Breast Care 12, 374–377.


Huss, A., Hasenburg, A., Oehler, M., and Klar, M. (2017a). The Mskcc Nomogram Is More Accurate in the Prediction of Overall Survival in a German Endometrial Cancer Patient Population Than the Figo Staging System. Int. J. Gynecol. Cancer 27, 209–209.


Huss, A., Hasenburg, A., Oehler, M., and Klar, M. (2017b). The Mskcc Nomogram Is More Accurate in the Prediction of Overall Survival in a German Endometrial Cancer Patient Population Than the Figo Staging System. Int. J. Gynecol. Cancer 27, 1111–1111.


Ishibashi, K., Haber, T., Breuksch, I., Gebhard, S., Sugino, T., Kubo, H., Hata, J., Koguchi, T., Yabe, M., Kataoka, M., et al. (2017). Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget 8, 55230–55245.


Klein, E., Beckmann, M.W., Bader, W., Brucker, C., Dobos, G., Fischer, D., Hanf, V., Hasenburg, A., Jud, S.M., Kalder, M., et al. (2017). Gynecologic oncologists’ attitudes and practices relating to integrative medicine: results of a nationwide AGO survey. Arch. Gynecol. Obstet. 296, 295–301.


Krajnak, S., Battista, M., Elger, T., Stewen, K., Heimes, A.S., Hasenburg, A., and Schmidt, M. (2017a). Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate. Int. J. Gynecol. Cancer 27, 116–116.


Krajnak, S., Battista, M., Elger, T., Stewen, K., Heimes, A.S., Hasenburg, A., and Schmidt, M. (2017b). Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate. Int. J. Gynecol. Cancer 27, 636–636.


Maurer, S., Elger, T., Krajnak, S., Heimes, A.S., Teifke, A., Kohlwes, E., Hasenburg, A., and Johannes, B.M. (2017). Axillary Schwannoma Imitating Axillary Cyst. Int. J. Gynecol. Cancer 27, 1298–1298.


Merzenich, H., Bartkowiak, D., Schmidberger, H., Schmidt, M., Schwentner, L., Wiegel, T., Woeckel, A., Wollschlaeger, D., and Blettner, M. (2017). 3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study). Breast Cancer Res. Treat. 161, 143–152.


Moebus, V., Hell, S., and Schmidt, M. (2017). Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer. Geburtshilfe Frauenheilkd. 77, 1079–1087.


Sagheb, K., Manz, A., Albrich, S.B., Taylor, K.J., Hess, G., and Walter, C. (2017). Supraclavicular Metastases from Distant Primary Solid Tumours: A Retrospective Study of 41 Years. J. Maxillofac. Oral. Surg. 16, 152–157.


Schmidt, M., Madjar, K., Heimes, A.-S., Battista, M., Lebrecht, A., Almsetdt, K., Hasenburg, A., Rahnenfhrer, J., and Hengstler, J.G. (2017). Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer. Cancer Res. 77.


Schwab, R., Battista, M.J.B., Kuenzel, K., Dionysopoulou, A., Bake, V., and Hasenburg, A. (2017). A Case of Uterine Relapse in a Young Woman with a History of All (acute Lymphoblastic Leukemia). Int. J. Gynecol. Cancer 27, 995–995.


Seidmann, L., Kamyshanskiy, Y., Martin, S.Z., Fruth, A., and Roth, W. (2017). Immaturity for gestational age of microvasculature and placental barrier in term placentas with high weight. Eur. J. Obstet. Gynecol. Reprod. Biol. 215, 134–140.


Thaler, S., Schmidt, M., Thiede, G., Schad, A., and Sleeman, J.P. (2017a). Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Cancer Res. 77.


Thaler, S., Schmidt, M., Rosswag, S., Thiede, G., Schad, A., and Sleeman, J.P. (2017b). Proteasome inhibitors prevent bi-directional HER2/estrogenreceptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget 8, 72281–72301.


Thill, M., Liedtke, C., Solomayer, E.-F., Mueller, V., Janni, W., and Schmidt, M. (2017). AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017. Breast Care 12, 184–191.

2016

Albrich, S., Steetskamp, J., Knoechel, S.-L., Porta, S., Hoffmann, G., and Skala, C. (2016). Assessment of pelvic floor muscle contractility: digital palpation versus 2D and 3D perineal ultrasound. Arch. Gynecol. Obstet. 293, 839–843.


Almstedt, K., and Schmidt, M. (2016). Immunotherapies for Breast Cancer - How Immune System and Cancer are associated and on what the Research works? Geburtshilfe Frauenheilkd. 76, 503–506.


Almstedt, K., Sicking, I., Huangfu, S., van de Sandt, L., Battista, M., Heimes, A.-S., Lebrecht, A., Hoffmann, G., Rahnenfuehrer, J., Hengstler, J., et al. (2016). Prognostic significance of focal adhesion kinase (FAK) in node-negative breast cancer (microarray based gene-expression- and immunohistochemistry-data). Oncol. Res. Treat. 39, 4–4.


Bartlett, J.M.S., Christiansen, J., Gustavson, M., Rimm, D.L., Piper, T., van de Velde, C.J.H., Hasenburg, A., Kieback, D.G., Putter, H., Markopoulos, C.J., et al. (2016). Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Arch. Pathol. Lab. Med. 140, 66–74.


Battista, M.J., and Schmidt, M. (2016). Fulvestrant for the treatment of endometrial cancer. Expert Opin. Investig. Drugs 25, 475–483.


Battista, M.J., Almstedt, K., Heimes, A.-S., Schmidt, M., Hoffmann, G., Eichbaum, M., Mallmann, P., and Steiner, E. (2016a). Management of recurrent and metastatic endometrial cancer in Germany: Results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. Oncol. Res. Treat. 39, 98–98.


Battista, M.J., Cotarelo, C., Almstedt, K., Heimes, A.-S., Makris, G.-M., Weyer, V., and Schmidt, M. (2016b). Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients. Arch. Gynecol. Obstet. 294, 599–606.


Battista, M.J., Goetze, K., Schmidt, M., Cotarelo, C., Weyer-Elberich, V., Hasenburg, A., Mueller-Klieser, W., and Walenta, S. (2016c). Feasibility of induced metabolic bioluminescence imaging in advanced ovarian cancer patients: first results of a pilot study. J. Cancer Res. Clin. Oncol. 142, 1909–1916.


Battista, M.J., Schmidt, M., Jakobi, S., Cotarelo, C., Almstedt, K., Heimes, A.-S., Makris, G.-M., Weyer, V., Lebrecht, A., Hoffmann, G., et al. (2016d). c-met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients. Oncol. Lett. 12, 2001–2007.


Bauer, H.-K., Heller, M., Fink, M., Maresch, D., Gartner, J., Gassner, U.M., and Al-Nawas, B. (2016). Social and legal frame conditions for 3D (and) bioprinting in medicine. Int. J. Comput. Dent. 19, 293–299.


Bayani, J., Yao, C.Q., Quintayo, M.A., Haider, S., Brookes, C.L., Yan, F., van de Velde, C.J.H., Hasenburg, A., Kieback, D.G., Markopoulos, C., et al. (2016). Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial. Cancer Res. 76.
du Bois, A., Ewald-Riegler, N., de Gregorio, N., Reuss, A., Mahner, S., Fotopoulou, C., Kommoss, F., Schmalfeldt, B., Hilpert, F., Fehm, T., et al. (2016). Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynakologische Onkologie AGO Study Group (vol 49, pg 1905, 2013). Eur. J. Cancer 65, 192–193.


Breuksch, I., Weinert, M., and Brenner, W. (2016). The role of extracellular calcium in bone metastasis. J. Bone Oncol. 5, 143–145.


Cotarelo, C.L., Schad, A., Kirkpatrick, C.J., Sleeman, J.P., Springer, E., Schmidt, M., and Thaler, S. (2016). Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes. Oncotarget 7, 74846–74859.


Farthmann, J., and Hasenburg, A. (2016). Oncology Sexuality after gynecological oncology Cancer and Breast Cancer. Geburtshilfe Frauenheilkd. 76, 231–233.


Farthmann, J., Hanjalic-Beck, A., Veit, J., Rautenberg, B., Stickeler, E., Erbes, T., Foeldi, M., and Hasenburg, A. (2016). The impact of chemotherapy for breast cancer on sexual function and health-related quality of life. Support. Care Cancer 24, 2603–2609.


Finn, R.S., Crown, J.P., Ettl, J., Schmidt, M., Bondarenko, I.M., Lang, I., Pinter, T., Boer, K., Patel, R., Randolph, S., et al. (2016). Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 18, 67.


Gomez, R., Schorsch, M., Hahn, T., Henke, A., Hoffmann, I., Seufert, R., and Skala, C. (2016). The influence of AMH on IVF success. Arch. Gynecol. Obstet. 293, 667–673.


Heimes, A.-S., van de Sandt, L., Edlund, K., Battista, M., Sicking, I., Almstedt, K., Lebrecht, A., Rahnenfuehrer, J., Hengstler, J.G., and Schmidt, M. (2016). Prognostic impact of interferon regulating factor 4 (IRF4) in node-negative breast cancer. Oncol. Res. Treat. 39, 45–45.


Heller, M., Bauer, H.-K., Goetze, E., Gielisch, M., Roth, K.E., Maier, G.S., Drees, P., Dorweiler, B., Ghazy, A., Neufurth, M., et al. (2016a). Applications of patient-specific 3D printing in medicine. Int. J. Comput. Dent. 19, 323–339.


Heller, M., Bauer, H.-K., Goetze, E., Gielisch, M., Ozbolat, I.T., Moncal, K.K., Rizk, E., Seitz, H., Gelinsky, M., Schrder, H.C., et al. (2016b). Materials and scaffolds in medical 3D printing and bioprinting in the context of bone regeneration. Int. J. Comput. Dent. 19, 301–321.


Hellwig, B., Madjar, K., Edlund, K., Marchan, R., Cadenas, C., Heimes, A.-S., Almstedt, K., Lebrecht, A., Sicking, I., Battista, M.J., et al. (2016). Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy. PLoS One 11, e0167585.


Hilbert, F., Gropp-Meier, M., Schmalfeldt, B., Rau, J., Meier, W., Hasenburg, A., Belau, A., Vergote, I., Zorr, A., Hils, R., et al. (2016). Patient-reported outcome (PRO) results from the AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomised phase III trial evaluating chemotherapy +/- pertuzumab for platinum-resistant ovarian cancer (PROC). Oncol. Res. Treat. 39, 138–138.


Kalder, M., Mueller, T., Fischer, D., Mueller, A., Bader, W., Beckmann, M.W., Brucker, C., Hack, C.C., Hanf, V., Hasenburg, A., et al. (2016). A Review of Integrative Medicine in Gynaecological Oncology. Geburtshilfe Frauenheilkd. 76, 150–155.


Kidszun, A., Linebarger, J., Walter, J.K., Paul, N.W., Fruth, A., Mildenberger, E., and Lantos, J.D. (2016). What If the Prenatal Diagnosis of a Lethal Anomaly Turns Out to Be Wrong? Pediatrics 137, e20154514.
Klar, M., Hasenburg, A., Hasanov, M., Hilpert, F., Meier, W., Pfisterer, J., Pujade-Lauraine, E., Herrstedt, J., Reuss, A., and du Bois, A. (2016). Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. Eur. J. Cancer 66, 114–124.


Laakmann, E., Witzel, I., Fehm, T., Hesse, I., von Minckwitz, G., Moebus, V., Park-Simon, T.-W., Neunhoeffer, I., Schmidt, M., Loibl, S., et al. (2016). Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): The introduction of the multicenter register and analysis of patient data. Oncol. Res. Treat. 39, 50–50.


Lambers, K., Hasenburg, A., Stickeler, E., Gitsch, G., Grosu, A.L., Henne, K., and Farthmann, J. (2016). Customized treatment of recurrent gynaecological cancer - the need for intraoperative radiation therapy. Eur. J. Gynaecol. Oncol. 37, 48–52.


Loibl, S., Furlanetto, J., Barinoff, J., Bauerschlag, D., Herr, D., Luebbe, K., Maass, N., Mueller, V., Mundhenke, C., Schmidt, M., et al. (2016). DESIREE - A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer. Cancer Res. 76.


Mahner, S., Lueck, H.-J., Grischke, E.-M., Rau, J., Gropp-Meier, M., Schmalfeldt, B., Meier, W., Hasenburg, A., Belau, A., Vergote, I., et al. (2016). Chemotherapy (CT) +/- pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase 3 trial. Oncol. Res. Treat. 39, 97–97.


Makris, G.M., Poulakaki, N., Battista, M.J., Boehm, D., Petraki, K., Bafaloukos, D., Sergentanis, T., Siristatidis, C., Chrelias, C., and Papantoniou, N. (2016a). Recurrence In Ductal Carcinoma In Situ And Molecular Subtypes. Int. J. Gynecol. Cancer 26, 49–50.


Makris, G.-M., Charalampopoulos, A., Siristatidis, C., Fexi, D., Chrelias, C., Battista, M.-J., and Papantoniou, N. (2016b). Y-type Anovulvar Fistula Complicating Inflammatory Bowel Disease. Am. Surg. 82, E305–E307.


Marme, F., Grischke, E.-M., Gropp-Meier, M., Rau, J., Schmalfeldt, B., Meier, W., Hasenburg, A., Belau, A., Vergote, I., Zorr, A., et al. (2016). Biomarker results from PENELOPE, A randomised phase III trial evaluating chemotherapy (CT) +/- pertuzumab (P) for platinum-resistant ovarian cancer (PROC) with low tumor HER3 mRNA expression. Oncol. Res. Treat. 39, 94–94.


Pannenbeckers, M., Derigs, P., Fruth, A., Paschen, A., Woelfel, T., and Woelfel, C. (2016). Detection of HLA-independent tumor-reactive T cells in umbilical cord blood. Oncol. Res. Treat. 39, 137–137.


Poulakaki, N., Makris, G.-M., Battista, M.-J., Boehm, D., Petraki, K., Bafaloukos, D., Sergentanis, T.N., Siristatidis, C., Chrelias, C., and Papantoniou, N. (2016). Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast? Breast 25, 57–61.


Radosa, J.C., Radosa, C.G., Kastl, C., Mavrova, R., Gabriel, L., Graeber, S., Wagenpfeil, G., Baum, S., Hamza, A., Joukhadar, R., et al. (2016). Influence of the Preoperative Decision-Making Process on the Postoperative Outcome after Hysterectomy for Benign Uterine Pathologies. Geburtshilfe Frauenheilkd. 76, 383–389.


Reif, R., Adawy, A., Vartak, N., Schroeder, J., Guenther, G., Ghallab, A., Schmidt, M., Schormann, W., and Hengstler, J.G. (2016). Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells. J. Biol. Chem. 291, 3837–3847.


Schmidt, M. (2016a). Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index. Breast Care 11, 22–26.


Schmidt, M. (2016b). Palbociclib - from Bench to Bedside and Beyond. Breast Care 11, 177–181.
Schmidt, M., van de Sandt, L., Heimes, A.-S., Battista, M., Lebrecht, A., Almstedt, K., Hoffmann, G., Rahnenfuehrer, J., and Hengstler, J.G. (2016a). Prognostic significance of immune checkpoint receptors in node-negative breast cancer. Cancer Res. 76.


Schmidt, M., Thomssen, C., and Untch, M. (2016b). Intrinsic Subtypes of Primary Breast Cancer - Gene Expression Analysis. Oncol. Res. Treat. 39, 102–110.


Schneeweiss, A., Forster, F., Tesch, H., Aktas, B., Gluz, O., Geberth, M., Hertz-Eichenrode, M.M., Schonegg, W., Schumacher, C., Kutscheidt, A., et al. (2016). First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. Anticancer Res. 36, 967–974.


Schneider, M., Schmeh, I., Fruth, A., Whybra-Truempler, C., and Mildenberger, E. (2016). Female Preterm Monozygotic Twins Discordant for Fetal Megacystis due to Cloacal Dysgenesis After Conception by Intracytoplasmatic Sperm Injection - Case Report and Review of Literature. Z. Geburtsh. Neonat. 220, 223–227.


Schnuerch, H.G., Ackermann, S., Alt, C.D., Barinoff, J., Boeing, C., Dannecker, C., Gieseking, F., Guenthert, A., Hantschmann, P., Horn, L.C., et al. (2016). Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015. Geburtshilfe Frauenheilkd. 76, 1035–1048.


Thiel, F.C., Parvanta, P., Hein, A., Mehlhorn, G., Lux, M.P., Renner, S.P., Preisner, A., Beckmann, M.W., and Schrauder, M.G. (2016). Chylous Ascites After Lymphadenectomy for Gynecological Malignancies. J. Surg. Oncol. 114, 613–618.


Van der Ven, H., Liebenthron, J., Beckmann, M., Toth, B., Korell, M., Kruessel, J., Frambach, T., Kupka, M., Hohl, M.K., Winkler-Crepaz, K., et al. (2016). Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates. Hum. Reprod. 31, 2031–2041.


Vdovichenko, N., Ataseven, B., Heitz, F., Prader, S., Schneider, S., Kurzeder, C., Heikaus, S., Weikel, W., Fisseler-Eckhoff, A., Alexander, T., et al. (2016). Fertility-sparing surgery (FSS) in patients with borderline ovarian tumors (BOT). Oncol. Res. Treat. 39, 92–92.


Witzel, I., Loibl, S., Laakmann, E., Augustin, D., Flock, F., Dohmen, H.-H., Durmus, G., Frank, M., Hesse, T., Ignatov, A., et al. (2016). Brain metastases in breast cancer network Germany (BMBC, GBG 79): First analysis of 548 patients from the multicenter registry. Cancer Res. 76.


Woelber, L., Griebel, L.-F., Eulenburg, C., Sehouli, J., Jueckstock, J., Hilpert, F., de Gregorio, N., Hasenburg, A., Ignatov, A., Hillemanns, P., et al. (2016). Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynakologische Onkologie CaRE-1 multicenter study. Eur. J. Cancer 69, 180–188.


Zhang, Y., Zhao, X., Leonhart, R., Nadig, M., Hasenburg, A., Wirsching, M., and Fritzsche, K. (2016). A cross-cultural comparison of climacteric symptoms, self-esteem, and perceived social support between Mosuo women and Han Chinese women. Menopause-J. N. Am. Menopause Soc. 23, 784–791.

2015

Albrich, S., Rommens, K., Steetskamp, J., Weyer, V., Hoffmann, G., Skala, C., and Zahn, E. (2015a). Prevalence of Levator Ani Defects in Urogynecological Patients. Geburtshilfe Frauenheilkd. 75, 51–55.
Albrich, S.B., Shek, K., Krahn, U., and Dietz, H.P. (2015b). Measurement of subpubic arch angle by three-dimensional transperineal ultrasound and impact on vaginal delivery. Ultrasound Obstet. Gynecol. 46, 496–500.


Almstedt, K., and Schmidt, M. (2015). Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Breast Care 10, 168–172.


Battista, M.J., Schmidt, M., Eichbaum, M., Almstedt, K., Heimes, A.-S., Mallmann, P., Hoffmann, G., and Steiner, E. (2015a). Management of recurrent or metastatic endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. Arch. Gynecol. Obstet. 292, 1355–1360.


Battista, M.J., Schmidt, M., Rieks, N., Sicking, I., Albrich, S., Eichbaum, M., Koelbl, H., Mallmann, P., Hoffmann, G., and Steiner, E. (2015b). Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. J. Cancer Res. Clin. Oncol. 141, 555–562.


Denkert, C., von Minckwitz, G., Brase, J.C., Sinn, B.V., Gade, S., Kronenwett, R., Pfitzner, B.M., Salat, C., Loi, S., Schmitt, W.D., et al. (2015). Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. J. Clin. Oncol. 33, 983–991.


Eichbaum, M.H.R., Schmidt, M., Grischke, E.-M., Gebauer, G., Fricke, H.-C., Lenz, F., Bischofs, E., Wallwiener, M., Marme, F., Schneeweiss, A., et al. (2015). The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer. J. Clin. Oncol. 33.


Finn, R.S., Crown, J., Lang, I., Kulyk, S.O., Schmidt, M., Patel, R., Thummala, A., Bondarenko, I., Randolph, S., Kim, S., et al. (2015a). The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2-metastatic breast cancer (MBC): Subanalysis from a randomized phase II study. J. Clin. Oncol. 33.


Finn, R.S., Crown, J.P., Lang, I., Boer, K., Bondarenko, I.M., Kulyk, S.O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015b). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25–35.


Karn, T., Pusztai, L., Liedtke, C., Bianchini, G., Gyoerffy, B., Hatzis, C., Rody, A., Mueller, V., Schmidt, M., Holtrich, U., et al. (2015). Gene expression associated with poor prognosis of young TNBC patients. Cancer Res. 75.


Laterza, R.M., Schrutka, L., Umek, W., Albrich, S., and Koelbl, H. (2015). Pelvic floor dysfunction after levator trauma 1-year postpartum: a prospective case-control study. Int. Urogynecol. J. 26, 41–47.
Lohr, M., Hellwig, B., Edlund, K., Mattsson, J.S.M., Botling, J., Schmidt, M., Hengstler, J.G., Micke, P., and Rahnenfuehrer, J. (2015). Identification of sample annotation errors in gene expression datasets. Arch. Toxicol. 89, 2265–2272.


Sahu, S.K., Garding, A., Tiwari, N., Thakurela, S., Toedling, J., Gebhard, S., Ortega, F., Schmarowski, N., Berninger, B., Nitsch, R., et al. (2015). JNK-dependent gene regulatory circuitry governs mesenchymal fate. Embo J. 34, 2162–2181.


Schmidt, M., van de Sandt, L., Almstedt, K., Battista, M.J., Heimes, A.-S., Lebrecht, A., Hoffmann, G., Rahnenfuehrer, J., and Hengstler, J.G. (2015a). Prognostic significance of Focal Adhesion Kinase (FAK) in node-negative breast cancer. J. Clin. Oncol. 33.


Schmidt, M., van de Sandt, L., Edlund, K., Sicking, I., Battista, M., Heimes, A.-S., Lebrecht, A., Hoffmann, G., Gehrmann, M., Rahnenfuehrer, J., et al. (2015b). Prognostic significance of the interferon metagene in node-negative breast cancer depends on the molecular subtype. Cancer Res. 75.


Slamon, D.J., Crown, J., Lang, I., Kulyk, S.O., Schmidt, M., Patel, R., Thummala, A., Voytko, N.L., Randolph, S., Kim, S., et al. (2015). Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2-advanced breast cancer (ABC) (PALOMA-1/TRIO-18). J. Clin. Oncol. 33.


Stock, A.-M., Klee, F., Edlund, K., Grinberg, M., Hammad, S., Marchan, R., Cadenas, C., Niggemann, B., Zaenker, K.S., Rahnenfuehrer, J., et al. (2015). Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptor-positive Breast Cancer. Anticancer Res. 35, 5277–5285.


Thaler, S., Thiede, G., Hengstler, J.G., Schad, A., Schmidt, M., and Sleeman, J.P. (2015). The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. Int. J. Cancer 137, 686–697.

2014

Battista, M.J., Cotarelo, C., Jakobi, S., Steetskamp, J., Makris, G., Sicking, I., Weyer, V., and Schmidt, M. (2014a). Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients. J. Cancer Res. Clin. Oncol. 140, 1097–1102.


Battista, M.J., Mantai, N., Sicking, I., Cotarelo, C., Weyer, V., Lebrecht, A., Solbach, C., and Schmidt, M. (2014b). Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: Results of an explorative, retrospective study. Oncol. Rep. 31, 2213–2219.


Battista, M.J., Schmidt, M., Rieks, N., Steetskamp, J., Sicking, I., Lebrecht, A., Koelbl, H., Mallmann, P., Hoffmann, G., and Steiner, E. (2014c). Nationwide analysis on surgical procedures for patients with endometrial cancer in Germany: Results of the AGO pattern of care studies from the years 2013, 2009, and 2006. J. Cancer Res. Clin. Oncol. 140, 2087–2093.


Boettcher, B., Laterza, R.M., Wildt, L., Seufert, R.J., Buhling, K.J., Singer, C.F., Hill, W., Griffin, P., Jilma, B., Schulz, M., et al. (2014). A first-in-human study of PDC31 (prostaglandin F-2 alpha receptor inhibitor) in primary dysmenorrhea. Hum. Reprod. 29, 2465–2473.


Cadenas, C., van de Sandt, L., Edlund, K., Lohr, M., Hellwig, B., Marchan, R., Schmidt, M., Rahnenfuehrer, J., Oster, H., and Hengstler, J.G. (2014). Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle 13, 3282–3291.


Godoy, P., Cadenas, C., Hellwig, B., Marchan, R., Stewart, J., Reif, R., Lohr, M., Gehrmann, M., Rahnenfuehrer, J., Schmidt, M., et al. (2014). Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response. Breast Cancer 21, 491–499.


Gomez, R., Schorsch, M., Steetskamp, J., Hahn, T., Heidner, K., Seufert, R., and Skala, C.E. (2014). The effect of ovarian stimulation on the outcome of intrauterine insemination. Arch. Gynecol. Obstet. 289, 181–185.


Heitz, F., Amant, F., Fotopoulou, C., Battista, M.J., Wimberger, P., Traut, A., Fisseler-Eckhoff, A., Harter, P., Vandenput, I., Sehouli, J., et al. (2014). Synchronous Ovarian and Endometrial Cancer-an International Multicenter Case-Control Study. Int. J. Gynecol. Cancer 24, 54–60.


Honig, A., Gehrmann, M., Kranke, P., Keller, D., Engel, J.B., Hengstler, J., and Schmidt, M. (2014). Microtubule-associated protein tau correlates with estrogen receptor status but not with in vitro paclitaxel sensitivity in primary breast cancer. Eur. J. Gynaecol. Oncol. 35, 503–507.


Jackisch, C., Welslau, M., Schoenegg, W., Selbach, J., Harich, H.-D., Schroeder, J., Schmidt, M., Goehler, T., Eustermann, H., Ringel, R., et al. (2014). Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - Results from a prospective, observational study in Germany. Breast 23, 603–608.


Kuhtz, J., Schneider, E., El Hajj, N., Zimmermann, L., Fust, O., Linek, B., Seufert, R., Hahn, T., Schorsch, M., and Haaf, T. (2014). Epigenetic heterogeneity of developmentally important genes in human sperm: Implications for assisted reproduction outcome. Epigenetics 9, 1648–1658.


Mayer, A., Schmidt, M., Seeger, A., Serras, F.A., Vaupel, P., and Schmidberger, H. (2014a). Microregional mismatch of markers related to hypoxia and the Warburg effect in squamous cell carcinomas of the vulva. Strahlenther. Onkol. 190, 82–83.


Mayer, A., Schmidt, M., Seeger, A., Serras, A.F., Vaupel, P., and Schmidberger, H. (2014b). GLUT-1 expression is largely unrelated to both hypoxia and the Warburg phenotype in squamous cell carcinomas of the vulva. BMC Cancer 14, 760.


Milde-Langosch, K., Karn, T., Schmidt, M., Eulenburg, C.Z., Oliveira-Ferrer, L., Wirtz, R.M., Schumacher, U., Witzel, I., Schuetze, D., and Mueller, V. (2014). Prognostic relevance of glycosylation-associated genes in breast cancer. Breast Cancer Res. Treat. 145, 295–305.


Schmidt, M. (2014). Chemotherapy in Early Breast Cancer: When, How and Which One? Breast Care 9, 154–160.


Schmidt, M., and Untch, M. (2014). Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer-a problem still to be solved. Ann. Oncol. 25, 754–754.


Schmidt, M., Hellwig, B., Sicking, I., Battista, M., Gebhard, S., Lebrecht, A., Gehrmann, M., Wirtz, R., Hoffmann, G., Solbach, C., et al. (2014). Comparison of the prognostic significance of immunoglobulin kappa C, CD4 and CD8 in node-negative breast cancer. Oncol. Res. Treat. 37, 2–2.


Schorsch, M., Hahn, T., Turley, H., and Seufert, R. (2014). Blastocyst formation, pregnancy and birth (more than 10 years after the birth of the first child from the same IVF cycle), derived from human PN-stage cryopreserved for 10 years. Arch. Gynecol. Obstet. 289, 227–228.


Sicking, I., Edlund, K., Wesbuer, E., Weyer, V., Battista, M.J., Lebrecht, A., Solbach, C., Grinberg, M., Lotz, J., Hoffmann, G., et al. (2014a). Prognostic Influence of Pre-Operative C-Reactive Protein in Node-Negative Breast Cancer Patients. PLoS One 9, e111306.


Sicking, I., Rommens, K., Battista, M.J., Boehm, D., Gebhard, S., Lebrecht, A., Cotarelo, C., Hoffmann, G., Hengstler, J.G., and Schmidt, M. (2014b). Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients. BMC Cancer 14, 952.


Tunn, R., Albrich, S., Beilecke, K., Kociszewski, J., Lindig-Knopke, C., Reisenauer, C., Schwertner-Tiepelmann, N., Kuhn, A., Viereck, V., Radisic, V.B., et al. (2014). Interdisciplinary S2k Guideline: Sonography in Urogynecology Short Version - AWMF Registry Number: 015/055. Geburtshilfe Frauenheilkd. 74, 1093–1098.


Wege, A.K., Schmidt, M., Ueberham, E., Ponnath, M., Ortmann, O., Brockhoff, G., and Lehmann, J. (2014). Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice A novel approach to generate tumor cell specific human antibodies. MAbs 6, 968–977.

2013

Barinoff, J., Traut, A., Bauerschlag, D., Bischoff, J., Herr, D., Luebbe, K., Lueck, H.-J., Maass, N., Mundhenke, C., Schmidt, M., et al. (2013). Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group. Geburtshilfe Frauenheilkd. 73, 433–439.


Battista, M., Mantai, N., Makris, G., Sicking, I., Weyer, V., Cotarelo, C., and Schmidt, M. (2013a). Proliferation (ki-67) and Endocrine Regulation (progesterone Receptor) Correlate with Prognosis in Ovarian Cancer - Invasion (upa and Pai-1) Does Not. Int. J. Gynecol. Cancer 23.


Battista, M.J., Steiner, E., Rieks, N., Steetskamp, J., Seeger, A., Sicking, I., Boehm, D., Schmidt, M., and Koelbl, H. (2013b). Nationwide Analysis on Surgical Staging Procedures and Systemic Treatment for Patients With Endometrial Cancer in Germany. Int. J. Gynecol. Cancer 23, 105–112.


Bianchini, G., Pusztai, L., Karn, T., Iwamoto, T., Rody, A., Kelly, C.M., Mueller, V., Schmidt, M., Qi, Y., Holtrich, U., et al. (2013). Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Res. 15, R86.


Dubsky, P., Brase, J.C., Jakesz, R., Rudas, M., Singer, C.F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., et al. (2013a). The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients. Br. J. Cancer 109, 2959–2964.


Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C.F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., et al. (2013b). EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann. Oncol. 24, 640–647.


Harbeck, N., Schmitt, M., Meisner, C., Friedel, C., Untch, M., Schmidt, M., Sweep, C.G.J., Lisboa, B.W., Lux, M.P., Beck, T., et al. (2013). Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur. J. Cancer 49, 1825–1835.


Heitz, F., Amant, F., Fotopoulou, C., Battista, M.J., Wimberger, P., Vandenput, I., Sehouli, J., Schmidt, M., Kimmig, R., and du Bois, A. (2013). Synchronous Ovarian and Endometrial Cancer - an International Multicenter Case-Control Study. Int. J. Gynecol. Cancer 23.


Kneist, W., Kauff, D.W., Naumann, G., and Lang, H. (2013). Resection rectopexy-laparoscopic neuromapping reveals neurogenic pathways to the lower segment of the rectum: preliminary results. Langenbecks Arch. Surg. 398, 565–570.


Lehr, H.-A., Rochat, C., Schaper, C., Nobile, A., Shanouda, S., Vijgen, S., Gauthier, A., Obermann, E., Leuba, S., Schmidt, M., et al. (2013). Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas. Mod. Pathol. 26, 336–342.


Maass, N., Harbeck, N., Mundhenke, C., Lerchenmueller, C., Barinoff, J., Lueck, H.-J., Ettl, J., Aktas, B., Kuemmel, S., Roesel, S., et al. (2013). Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J. Cancer Res. Clin. Oncol. 139, 2047–2056.


Milde-Langosch, K., Karn, T., Mueller, V., Witzel, I., Rody, A., Schmidt, M., and Wirtz, R.M. (2013). Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res. Treat. 137, 57–67.


von Minckwitz, G., Martin, M., Wilson, G., Alba, E., Schmidt, M., Biganzoli, L., and Awada, A. (2013a). Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Crit. Rev. Oncol./Hematol. 85, 315–331.


von Minckwitz, G., Moebus, V., Schneeweiss, A., Huober, J., Thomssen, C., Untch, M., Jackisch, C., Diel, I.J., Elling, D., Conrad, B., et al. (2013b). German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer. J. Clin. Oncol. 31, 3531–3539.


Rodriguez-Lescure, A., Brase, J.C., Schmidt, M., Gehrmann, M., Ruiz, A., Ruiz Borrego, M., Munarriz, B., Rodriguez, C.A., Calvo, L., and Martin, M. (2013). Biomarkers for predicting taxane efficacy in ER+/HER2-breast cancer patients: From in-vitro chemosensitivity screening to clinical validation in the GEICAM/ 9906 trial. Eur. J. Cancer 49, S475–S475.


Schmidt, M. (2013). Gene expression signatures in breast cancer. Onkologe 19, 465–+.
Schmidt, M., Micke, P., and Hengstler, J.G. (2013). IGKC and Prognosis in Breast Cancer-Letter. Clin. Cancer Res. 19, 304–304.


Schuetze, D., Milde-Langosch, K., Witzel, I., Rody, A., Karn, T., Schmidt, M., Choschzick, M., Jaenicke, F., and Muller, V. (2013). Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer. J. Cancer Res. Clin. Oncol. 139, 747–754.


Wagner, M., Koslowski, M., Paret, C., Schmidt, M., Tuereci, O., and Sahin, U. (2013). NCOA3 is a selective co-activator of estrogen receptor alpha-mediated transactivation of PLAC1 in MCF-7 breast cancer cells. BMC Cancer 13, 570.


Witzel, I., Graeser, M., Karn, T., Schmidt, M., Wirtz, R., Schuetze, D., Rausch, A., Jaenicke, F., Milde-Langosch, K., and Mueller, V. (2013). Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. J. Cancer Res. Clin. Oncol. 139, 809–816.